To view this email as a web page, click here.
September 19, 2019
 
New Treatment Option for Systemic Sclerosis-Associated Interstitial Lung Disease
The U.S. Food and Drug Administration has approved nintedanib (Ofev, Boehringer Ingelheim Pharmaceuticals) capsules to slow the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD), which is a progressive lung disease that can be debilitating and life-threatening.
Read more
 
Osteoarthritis News Roundup: Opioids, NSAIDs and More
In today's news roundup, we focus on recent advances made in osteoarthritis that touch on cardiovascular issues, bone spurs and treatment modalities.
Read more
 
Knee Osteoarthritis Pain Intensity is Gender-Related
Levels of the biomarker urine C-telopeptide of cross-linked collagen type II (uCTX-II) are independently associated with radiographic severity and pain intensity in knee osteoarthritis, say researchers writing in Arthritis Research & Therapy this month.
Read more
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.